Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase 2 Withdrawn
Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma
Phase 1 Withdrawn
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Phase 1 Withdrawn
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Phase 1 Withdrawn
Re-Induce 2
Phase 2 Withdrawn
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
Phase 1 Withdrawn
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1 Withdrawn
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
Phase 1 Withdrawn
PANTHEoN
Phase 1 Withdrawn
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Phase 2 Withdrawn
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
Phase 2 Withdrawn
Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma
Phase NA Withdrawn
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients
Phase 2 Withdrawn
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Phase 2 Withdrawn
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Phase 2 Withdrawn
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Phase 1 Withdrawn
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Phase 1 Withdrawn
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Phase 2/3 Withdrawn
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
Phase 2 Withdrawn
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
Phase 2 Withdrawn
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
Phase 1/2 Withdrawn
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
Phase 2/3 Withdrawn
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Withdrawn
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Phase 2 Withdrawn
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Phase 2 Withdrawn
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Phase 2 Withdrawn
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Phase 1 Withdrawn
A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients
Phase NA Withdrawn
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Phase 2 Withdrawn
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Phase 1 Withdrawn
PMABIIS
Phase 2 Withdrawn
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
Phase 1/2 Withdrawn
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Phase 2 Withdrawn